Table of Contents
A narrative review indexed on NIH platforms examined the possible mechanisms by which psilocybin could support recovery from traumatic brain injury, focusing on neuroplasticity pathways. The review is theoretical and descriptive, not a clinical trial, and no conclusions about human treatment can be drawn from it at this stage.
- This is a narrative review, not a clinical trial. The authors synthesized existing literature to map plausible biological pathways, not to test psilocybin in TBI patients directly.
- Neuroplasticity is the central mechanism explored. The review focuses on how psilocybin may influence the brain’s ability to reorganize and form new connections, which is relevant to injury recovery.
- No dosing or treatment protocol is established. Nothing in a narrative review of this kind can be read as a recommendation for use in TBI patients.
- The work signals a growing research interest. Formal clinical trials in TBI populations would be needed before any therapeutic conclusions could be drawn.
- Model
- human (narrative review of existing literature)
- Sample
- No trial participants; review of prior research
- Design
- Narrative review
- Key outcome
- Identification of neuroplasticity-related mechanisms by which psilocybin may theoretically support TBI recovery
- Main limitation
- No original data; no clinical trial participants; conclusions are speculative and hypothesis-generating only
What the Research Examined
This entry is based on a narrative review indexed through the National Institutes of Health, published in May 2025, which examined the theoretical role psilocybin might play in traumatic brain injury recovery. A narrative review is a synthesis of existing published literature, not an original experiment or clinical trial. The authors did not administer psilocybin to any participants. Instead, they mapped the biological and neurochemical pathways that prior research has associated with psilocybin and asked whether those pathways might be relevant to the challenges TBI recovery presents. You can find the primary source via NIH’s research indexing using the review’s title.
The central thread of the review is neuroplasticity, meaning the brain’s capacity to rewire, strengthen, or form new neural connections following damage. Psilocybin has drawn scientific interest in this area because early research in other contexts suggests it may promote synaptogenesis and influence serotonin receptor pathways in ways that could theoretically support neural reorganization. For readers wanting broader context on psilocybin’s effects on the brain, the mechanisms discussed here overlap with findings from depression and PTSD research, though TBI presents its own distinct challenges and injury profiles.
It is worth being direct about what the source text provided: the available summary describes the review’s scope and focus at a high level, specifically neuroplasticity pathways and psilocybin’s potential mechanisms. The underlying review itself, including any specific studies cited, molecular pathways detailed, or conclusions reached by the authors, would need to be read in full to be reported with greater precision. What can be stated clearly is that this is a hypothesis-generating piece of scholarship, not evidence of efficacy in TBI patients.
What the Findings Show
- Study type.Narrative review, meaning no new experimental data were generated. The authors synthesized prior literature rather than conducting a trial.
- Mechanism focus.The review centers on neuroplasticity pathways, the biological processes by which psilocybin may theoretically support the brain’s reorganization following traumatic injury.
- Population studied.No TBI patients were enrolled or treated. The review examines what existing psilocybin research might imply for TBI, not what has been directly tested in that population.
Because the available source text summarizes the review at a high level, specific statistics, effect sizes, or named studies cited within the review cannot be reported here without access to the full document. Readers with a clinical or research interest in this topic are encouraged to seek out the primary review through NIH’s indexing systems to evaluate the authors’ reasoning and citations directly.
Can psilocybin help with traumatic brain injury recovery?
Research on this question is at a very early, theoretical stage. A 2025 narrative review explored neuroplasticity mechanisms that might connect psilocybin to TBI recovery, but no clinical trials have tested this in TBI patients. It is far too soon to draw conclusions about benefit, safety, or dosing.
What This Is, and What It Is Not
This is This is a narrative review, a scholarly synthesis of existing literature that maps plausible mechanisms and identifies questions for future research.
This is not This is not a clinical trial, and it does not demonstrate that psilocybin is safe or effective for traumatic brain injury. Nothing in this review constitutes medical advice, and no one should alter their care based on it.
Our Take
Within our community, the relationship between mind, brain, and healing has always carried weight beyond the clinical. Traumatic brain injury can fracture a person’s sense of self and continuity in ways that are both neurological and deeply personal. The fact that researchers are now asking whether psilocybin, a compound long understood in contemplative traditions as a catalyst for inner reorganization, might also assist the literal reorganization of damaged neural tissue is worth sitting with quietly. We hold this possibility with care and patience, knowing that science moves in its own time, and that hope is not the same as evidence.
If this area of research touches something personal for you, whether you are navigating your own recovery, supporting someone who is, or simply curious about where the science is heading, we welcome you to stay close to this unfolding conversation. The work of Grounding and Integration that our community values most begins with honest information, and we will keep reporting it as carefully as we can. You belong here, whatever brought you to this door.
Frequently Asked Questions
What is a narrative review and why does it matter?
A narrative review synthesizes existing published studies to identify patterns, gaps, and plausible mechanisms. It does not generate new experimental data. It is useful for framing hypotheses and pointing toward where clinical trials should go next, but it cannot establish that a treatment works.
Has psilocybin been tested in human traumatic brain injury trials?
As of this review’s publication in May 2025, the source text does not describe any completed human clinical trials of psilocybin specifically in TBI patients. The review is exploratory, examining whether such trials would be scientifically justified.
What does neuroplasticity mean in the context of TBI recovery?
Neuroplasticity refers to the brain’s ability to form new connections, reorganize existing pathways, and compensate for damaged tissue. After a traumatic brain injury, supporting neuroplasticity is considered an important goal of rehabilitation, though how to do so effectively remains an active area of research.
Is psilocybin safe for people who have had a brain injury?
This question cannot be answered from the available evidence. A narrative review exploring theoretical mechanisms is not a safety study. Anyone with a history of traumatic brain injury should consult qualified medical professionals before considering any experimental or unapproved intervention.
Where can I read the full review?
The review is indexed through the National Institutes of Health. Searching the full title, ‘The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review,’ in PubMed or Google Scholar should surface the primary document or its abstract.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
